Dr. Amy Johnson on Research Into Acalabrutinib as a Treatment for CLL

December 11, 2015
Amy Johnson, PhD

Amy Johnson, PhD, discusses the overall high response rates in patients with chronic lymphocytic leukemia (CLL) to a new novel bruton tyrosine kinase (BTK) inhibitor called acalabrutinib (ACP-196).

Amy Johnson, PhD, associate professor, Hematology, Ohio State University, discusses the overall high response rates in patients with chronic lymphocytic leukemia (CLL) to a new novel bruton tyrosine kinase (BTK) inhibitor called acalabrutinib (ACP-196). Acalabrutinib is a selective, irreversible BTK inhibitor designed to improve both the safety and efficacy of BTK inhibitors in CLL.

Johnson says there is currently neither a subtype of patient with CLL that benefits from acalabrutinib, nor is there a subtype that suffers from the treatment.